What Effects Do Probiotics Have On Digestive Health?
Quick answer
Certain probiotic strains, such as Bacillus coagulans, multispecies probiotics including Bifidobacterium animalis subsp. lactis BB-12, Escherichia coli Nissle 1917, and Lacticaseibacillus rhamnosus GG, have shown evidence of helping alleviate digestive problems, particularly in functional dyspepsia and irritable bowel syndrome (IBS). However, effects vary by strain and condition, and some strains like Lactiplantibacillus plantarum 299v showed no significant benefit in IBS.
🔬 What the research shows
High-quality randomized controlled trials support the use of Bacillus coagulans MY01 and Bacillus subtilis MY02 for functional dyspepsia, showing improved symptom response compared to placebo. For IBS, multispecies probiotics containing Bifidobacterium animalis subsp. lactis BB-12, Lactobacillus rhamnosus GG, and others have demonstrated symptom relief and microbiota stabilization. Escherichia coli Nissle 1917 showed benefits mainly in IBS patients with prior gastroenteritis or antibiotic use. Lacticaseibacillus rhamnosus GG also showed symptom improvement in IBS. However, Lactiplantibacillus plantarum 299v did not show significant efficacy in IBS. Some studies suggest probiotics may help with digestive comfort in general populations, but more confirmatory trials are needed. Evidence for probiotics in dyspepsia related to Helicobacter pylori is low and mainly theoretical. Safety profiles are generally good with similar adverse event rates to placebo. Limitations include small sample sizes, heterogeneity of probiotic strains and IBS subtypes, and some open-label or pilot study designs.
Best studied probiotic strains
Bacillus coagulans MY01 and Bacillus subtilis MY02
High-quality RCT (PMID 34358486) showed higher clinical response rates in functional dyspepsia compared to placebo with good safety.
Effective in functional dyspepsia; studied as spore-forming probiotics.
Bifidobacterium animalis subsp. lactis BB-12 (part of multispecies probiotic)
High-quality RCT (PMID 17919270) showed symptom relief and microbiota stabilization in IBS patients.
Used in combination with other strains; benefits mainly in IBS.
Escherichia coli Nissle 1917
High-quality RCT (PMID 22130826) showed symptom improvement in IBS patients, especially those with prior gastroenteritis or antibiotic use.
Strain-specific benefit in IBS subgroups with altered microflora.
Lacticaseibacillus rhamnosus GG (part of probiotic mixtures)
High-quality RCTs (PMID 16128676) showed reduction in IBS symptoms compared to placebo.
Often studied as part of multispecies probiotic mixtures.
👥 Who may benefit
✅ Safety
Probiotics studied were generally safe with adverse event rates similar to placebo. Serious adverse events were rare and unlikely related to probiotic use.
⚠️ Limitations
Many studies have small sample sizes or pilot designs. Probiotic effects are strain-specific and may not generalize across all digestive problems. Some evidence is limited to IBS or functional dyspepsia and may not apply to other digestive conditions. More large-scale, double-blind RCTs are needed to confirm benefits and identify optimal strains and doses.